Possible contributions of thyroid hormone replacement to specific behaviors of cancer

Aleck Hercbergs, Paul J. Davis, Hung Yun Lin, Shaker A. Mousa

研究成果: 雜誌貢獻回顧型文獻

3 引文 斯高帕斯(Scopus)

摘要

L-Thyroxine (T4) is the principal replacement hormone for patients who have hypothyroidism. Some preclinical and clinical evidence supports the possibility that T4 can at least permissively affect certain features of established cancers and cancer-relevant angiogenesis. Thus, in the occasional patient with hypothyroidism and concomitant cancer, it appears reasonable to consider thyroid hormone replacement exclusively with 3,3′,5-triiodo-L-thyronine (T3). This use of T3 has been shown to be effective and safe in early experience with medical induction of euthyroid hypothyroxinemia in patients with advanced solid tumors.
原文英語
頁(從 - 到)655-659
頁數5
期刊Biomedicine and Pharmacotherapy
84
DOIs
出版狀態已發佈 - 十二月 1 2016

ASJC Scopus subject areas

  • Pharmacology

指紋 深入研究「Possible contributions of thyroid hormone replacement to specific behaviors of cancer」主題。共同形成了獨特的指紋。

  • 引用此